Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $5.92.

XERS has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday. Piper Sandler restated a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Craig Hallum lifted their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday. Finally, Leerink Partners raised their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday.

Xeris Biopharma Trading Up 2.2 %

Xeris Biopharma stock traded up $0.10 during mid-day trading on Monday, hitting $4.34. The company had a trading volume of 1,550,590 shares, compared to its average volume of 1,925,303. The company has a market capitalization of $646.27 million, a PE ratio of -9.63 and a beta of 2.32. Xeris Biopharma has a 12 month low of $1.69 and a 12 month high of $4.50. The stock’s 50 day moving average price is $3.57 and its two-hundred day moving average price is $3.26.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently added to or reduced their stakes in XERS. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Xeris Biopharma by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after purchasing an additional 2,954 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Xeris Biopharma by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock valued at $273,000 after buying an additional 3,447 shares in the last quarter. GPS Wealth Strategies Group LLC raised its holdings in shares of Xeris Biopharma by 6.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock worth $227,000 after buying an additional 3,900 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Xeris Biopharma by 31.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock valued at $78,000 after buying an additional 5,500 shares during the period. Finally, Prudential Financial Inc. raised its stake in shares of Xeris Biopharma by 23.4% during the 4th quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock worth $125,000 after buying an additional 7,000 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.